CN102078508A - Medicine for treating infantile respiratory tract recurrent infection, preparation method thereof and quality control method thereof - Google Patents
Medicine for treating infantile respiratory tract recurrent infection, preparation method thereof and quality control method thereof Download PDFInfo
- Publication number
- CN102078508A CN102078508A CN2011100041173A CN201110004117A CN102078508A CN 102078508 A CN102078508 A CN 102078508A CN 2011100041173 A CN2011100041173 A CN 2011100041173A CN 201110004117 A CN201110004117 A CN 201110004117A CN 102078508 A CN102078508 A CN 102078508A
- Authority
- CN
- China
- Prior art keywords
- parts
- solution
- medicine
- reference substance
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, and discloses a medicine for treating infantile respiratory tract recurrent infection, a preparation method thereof and a quality control method thereof. According to the theory of traditional Chinese medical science, a compound preparation is prepared from astragalus, dwarf lilyturf tuber, largehead atractylodes rhizome, Indian buead, Chinese magnoliavine fruit, dark plum fruit, tangerine peel, liquoric root and the like. The medicine has the effects of strengthening exterior and replenishing defensive qi, tonifying qi and spleen, astringing lung and promoting body fluid, defending the invasion of exogenous pathogens and the like, and is used for treating infantile respiratory tract recurrent infection.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of children respiratory repeated infection and preparation method thereof and quality determining method, belong to the field of Chinese medicines.
Background technology
Children respiratory repeated infection is usual diseases of childhood, frequently-occurring disease.Its pathogenesis is a result of various factor comprehensive action, and immunologic hypofunction is considered to its one of the main reasons.Sickness rate is on the rise in recent years.The treatment children respiratory repeated infection is primarily aimed at symptom at present, infection period is based on Coritab, weight person gives supporting treatment, lag phase is used immune formulation at the individual immunity situation, obtain certain curative effect as methods such as dead point gamma globulin, oral transfer factor oral liquids, but late result is not good enough.In recent years, domestic utilization traditional Chinese medical herbal treatment primary disease is obtained clinical efficacy preferably, Chinese medicine is determined curative effect on the control children respiratory repeated infection, clinical side reaction is rare, and late result is good especially, symptom to the children respiratory repeated infection infant in strengthening vital QI to eliminate pathogenic factors also plays therapeutical effect, has improved the body constitution and the quality of life of infant greatly.
Children's's internal organs are tender and lovely, and body constitution is childish and tender, and pathogen is easily violated.The Ming Dynasty doctor perfectly sound children's's of thinking of family " three have a surplus, four deficiencies " physiological and pathological feature.That is: YANG often being in excess, YIN often being in shortage, the liver being liable to excess, the spleen tending to insufficiency usually, heart-QI being liable to hyperactivity, the lung being usually insufficient, kidney are often not enough.The lung being usually insufficient is easy to feel exopathogen: the abundant Gu that freely all need depend on the gas of spleen kidney of transferring of lung qi protects; Right children's's spleen the kidney being always deficient, the easier void of lung then, the three influences each other, and makes healthy energy more empty, not anti-exopathogen invasion and attack.Therefore, the children respiratory repeated infection morbidity is closely related with the lung weakness of the spleen and kidney.
The court's self-control " wheat stilbene lung benefiting mixture " is comprehensively to form on the square basis at tradition " YUPINGFENG SAN ", " SHENGMAI YIN " " decoction of four noble drugs ", is made up of eight flavor medicines such as the Radix Astragali, Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, Poria, Fructus Schisandrae Chinensis, Fructus Mume, Pericarpium Citri Reticulatae, Radix Glycyrrhizae.Monarch drug in the Radix Astragali, the Radix Ophiopogonis side of being, the big tonifying the lung spleen of Radix Astragali vigour, consolidating superficial resistance is real to be defended; Radix Ophiopogonis YIN nourishing and the production of body fluid promoting, gas cloudy two is mended; Though the main gas of lung, its gas derives from the essential substances from water and cereals day after tomorrow, desires tonifying the lung gas, and spleen reinforcing in the ban is so join the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, Fructus Schisandrae Chinensis; Poria, sweet, light, gentle, be the key medicine of promoting diuresis to eliminate damp pathogen, the merit of spleen invigorating is arranged again; Pericarpium Citri Reticulatae, warm in nature, acrid in the mouth, hardship are returned the lung spleen channel, and function is a regulating qi-flowing for strengthening spleen, drying dampness to eliminate phlegm; Fructus Mume is used for chronic cough of deficiency lung, and the irritated effect of anti-albumen is arranged.All medicines share, the spleen invigorating lung benefiting, and deficiency and excess is also controlled, and giving consideration to both the incidental and fundamental has the real consolidating superficial resistance of defending. and air making-up and spleen enlivening, astringe the lung and promote the production of body fluid, functions such as defence exopathogen invasion and attack are used for children respiratory repeated infection.
Summary of the invention
The object of the invention is to provide a kind of Chinese medicine composition and preparation method thereof and quality determining method.
The present invention seeks to be achieved through the following technical solutions:
The raw material of Chinese medicine composition of the present invention is composed as follows:
Radix Astragali 3-18 part, Radix Ophiopogonis 2-12 part, Rhizoma Atractylodis Macrocephalae 3-18 part, Poria 3-18 part,
Fructus Schisandrae Chinensis 2-10 part, Fructus Mume 2-10 part, Pericarpium Citri Reticulatae 2-10 part, Radix Glycyrrhizae 2-8 part
The preferred weight proportioning of above-mentioned raw materials is as follows:
6 parts of the Radixs Astragali, 4 parts of Radix Ophiopogonis, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts in Poria,
4 parts of Fructus Schisandrae Chinensis, 4 parts of Fructus Mumes, 4 parts of Pericarpium Citri Reticulataes, 3 parts in Radix Glycyrrhizae
The preferred weight proportioning of above-mentioned raw materials is as follows:
9 parts of the Radixs Astragali, 6 parts of Radix Ophiopogonis, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts in Poria,
5 parts of Fructus Schisandrae Chinensis, 5 parts of Fructus Mumes, 5 parts of Pericarpium Citri Reticulataes, 4 parts in Radix Glycyrrhizae
The preferred weight proportioning of above-mentioned raw materials is as follows:
18 parts of the Radixs Astragali, 9 parts of Radix Ophiopogonis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts in Poria,
8 parts of Fructus Schisandrae Chinensis, 8 parts of Fructus Mumes, 10 parts of Pericarpium Citri Reticulataes, 8 parts in Radix Glycyrrhizae
Medicine material of the present invention according to common process, is made clinical acceptable oral administration solution.
The concrete preparation technology of Chinese medicine composition of the present invention is as follows:
Add multi-function extractor after getting eight flavor Chinese medicine weighings of weight proportion in the prescription, after water fully soaks, add water and cross powder 2-3 centimetre of decoction twice, 1.5 hours for the first time, 1 hour for the second time, decocting liquid filters, merge, soak to put and get supernatant concentration more than 12 hours, add sucrose 100g while hot to about 950ml, sodium benzoate 2 g stir evenly.
Quality determining method of the present invention comprises following discrimination method:
Discrimination method comprises a kind of and/or several in the following discriminating:
A: get Chinese medicine composition 20ml, extract 2 times with water saturated n-butyl alcohol jolting, each 20ml merge extractive liquid,, with ammonia solution washing 2 times, each 30 ml, the saturated water washing of reuse n-butyl alcohol 2 times, each 30 ml, n-butyl alcohol evaporate to dryness.Residue adds methanol test solution 1ml makes dissolving, as need testing solution.Other gets the astragaloside reference substance, adds methanol and makes the solution that per 1 ml contains 0.5mg, product solution in contrast.Draw above-mentioned test sample 5ul, reference substance solution 2ul, put respectively on same silica gel g thin-layer plate, placing stratified lower floor solution below 10 ℃ with chloroform-methanol-water (13:7:2) is developing solvent, launch, take out, airing, spray are with 10% sulphuric acid ethanol (V/V) solution, and it is clear to be heated to the speckle color at 105 ℃.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of identical color.
B: get Chinese medicine composition 20 ml, extract 2 times with the ethyl acetate jolting, each 20 ml merge ethyl acetate liquid, and evaporate to dryness, residue add methanol 1 ml makes dissolving, as need testing solution.Other gets the Hesperidin reference substance, adds methanol and makes saturated solution, in contrast product solution.Drawing above-mentioned two kinds of each 1ul of test liquid, put respectively on same polyamide film, is developing solvent with chloroform-acetone-methanol (5:1:1), launch, take out, dry, spray is placed more than 30 minutes with 2% aluminum chloride alcoholic solution, puts under the uviol lamp (365nm) and inspects.In the test sample chromatograph, be on the corresponding position of reference substance chromatograph, show the fluorescence speckle of same color.
C: get Chinese medicine composition 10ml, slowly Dropwise 5 0% sulfuric acid solution 1 ml leaves standstill and makes precipitation, centrifugal, abandoning supernatant, and precipitation washes with water 2 times, and each 10 ml get precipitation and add ethanol 5 ml and make dissolving, and are centrifugal, get supernatant as need testing solution.Extracting liquorice acid ammonium reference substance adds ethanol and makes the solution that per 1 ml contains 0.5mg, product solution in contrast in addition.Drawing above-mentioned need testing solution 15ul, reference substance solution 2ul, put respectively on same silica GF254 lamellae, is developing solvent with ethyl acetate-formic acid-glacial acetic acid-water (15:1:1:2), launches, and takes out, and dries, and puts under the uviol lamp (254nm) and inspects.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
The specific embodiment
Following experiment and example are used to further specify but are not limited to the present invention.
Embodiment 1:The preparation of Chinese medicine composition
6 parts of the Radixs Astragali, 4 parts of Radix Ophiopogonis, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts in Poria,
4 parts of Fructus Schisandrae Chinensis, 4 parts of Fructus Mumes, 4 parts of Pericarpium Citri Reticulataes, 3 parts in Radix Glycyrrhizae
Add multi-function extractor after getting eight flavor Chinese medicine weighings of weight proportion in the prescription, after water fully soaks, add water and cross powder 2-3 centimetre of decoction twice, 1.5 hours for the first time, 1 hour for the second time, decocting liquid filters, merge, soak to put and get supernatant concentration more than 12 hours, add sucrose 100g while hot to about 950ml, sodium benzoate 2 g stir evenly.
Embodiment 2:The preparation of Chinese medicine composition
9 parts of the Radixs Astragali, 6 parts of Radix Ophiopogonis, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts in Poria,
5 parts of Fructus Schisandrae Chinensis, 5 parts of Fructus Mumes, 5 parts of Pericarpium Citri Reticulataes, 4 parts in Radix Glycyrrhizae
Add multi-function extractor after getting eight flavor Chinese medicine weighings of weight proportion in the prescription, after water fully soaks, add water and cross powder 2-3 centimetre of decoction twice, 1.5 hours for the first time, 1 hour for the second time, decocting liquid filters, merge, soak to put and get supernatant concentration more than 12 hours, add sucrose 100g while hot to about 950ml, sodium benzoate 2 g stir evenly.
Embodiment 3:The preparation of Chinese medicine composition
18 parts of the Radixs Astragali, 9 parts of Radix Ophiopogonis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts in Poria,
8 parts of Fructus Schisandrae Chinensis, 8 parts of Fructus Mumes, 10 parts of Pericarpium Citri Reticulataes, 8 parts in Radix Glycyrrhizae
Add multi-function extractor after getting eight flavor Chinese medicine weighings of weight proportion in the prescription, after water fully soaks, add water and cross powder 2-3 centimetre of decoction twice, 1.5 hours for the first time, 1 hour for the second time, decocting liquid filters, merge, soak to put and get supernatant concentration more than 12 hours, add sucrose 100g while hot to about 950ml, sodium benzoate 2 g stir evenly.
Embodiment 4:Discrimination method in the quality testing
A: get embodiment 3 medicine 20ml, extract 2 times with water saturated n-butyl alcohol jolting, each 20ml merge extractive liquid,, with ammonia solution washing 2 times, each 30 ml, the saturated water washing of reuse n-butyl alcohol 2 times, each 30 ml, n-butyl alcohol evaporate to dryness.Residue adds methanol test solution 1 ml makes dissolving, as need testing solution.Other gets the astragaloside reference substance, adds methanol and makes the solution that per 1 ml contains 0.5mg, product solution in contrast.Draw above-mentioned test sample 5ul, reference substance solution 2ul, put respectively on same silica gel g thin-layer plate, placing stratified lower floor solution below 10 ℃ with chloroform-methanol-water (13:7:2) is developing solvent, launch, take out, airing, spray are with 10% sulphuric acid ethanol (V/V) solution, and it is clear to be heated to the speckle color at 105 ℃.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of identical color.
B: get embodiment 3 medicines 20 ml, extract 2 times with the ethyl acetate jolting, each 20 ml merge ethyl acetate liquid, and evaporate to dryness, residue add methanol 1 ml makes dissolving, as need testing solution.Other gets the Hesperidin reference substance, adds methanol and makes saturated solution, in contrast product solution.Drawing above-mentioned two kinds of each 1ul of test liquid, put respectively on same polyamide film, is developing solvent with chloroform-acetone-methanol (5:1:1), launch, take out, dry, spray is placed more than 30 minutes with 2% aluminum chloride alcoholic solution, puts under the uviol lamp (365nm) and inspects.In the test sample chromatograph, be on the corresponding position of reference substance chromatograph, show the fluorescence speckle of same color.
C: get embodiment 3 medicine 10ml, slowly Dropwise 5 0% sulfuric acid solution 1 ml leaves standstill and makes precipitation, centrifugal, abandoning supernatant, and precipitation washes with water 2 times, and each 10 ml get precipitation and add ethanol 5 ml and make dissolving, and are centrifugal, get supernatant as need testing solution.Extracting liquorice acid ammonium reference substance adds ethanol and makes the solution that per 1 ml contains 0.5mg, product solution in contrast in addition.Drawing above-mentioned need testing solution 15ul, reference substance solution 2ul, put respectively on same silica GF254 lamellae, is developing solvent with ethyl acetate-formic acid-glacial acetic acid-water (15:1:1:2), launches, and takes out, and dries, and puts under the uviol lamp (254nm) and inspects.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Embodiment 5:Medicine is to the equilibrated influence of asthma mice Th1/Th2
1. data and method
1.1 animal pharmaceuticals toxicity test: 40 mices are divided into test group and matched group at random, fasting be can't help water after 12 hours, and the disposable gastric infusion wheat of test group mice stilbene lung benefiting mixture 0.8ml/20g body weight (contains 2.08g crude drug/ml, 332.8g crude drug/kg, matched group give the equivalent normal saline.Observe 30min after the administration, 1h puts to death mice row pathologic finding after 14 days.
1.2 laboratory animal and grouping: 24 of health Balb/c mices in 8 age in week, male and female half and half, body weight 21.02 ± 1.46g, normal diet is fed, and laboratory temperature is 22 ~ 240C, and humidity is 55% ~ 65%.Be divided into normal control group (A group) at random: 6; Asthma group (B group): 6; Asthma+wheat stilbene lung benefiting mixture treatment group (C group): 6.
1.3 the foundation of systemic allergic airway disease asthma mouse model (B group): lumbar injection immunity stock solution, atomizing sucks and excites.The mouse sensitization method is promptly tested the 0th, 7,14 day lumbar injection 1% egg protein (OVA, Shanghai uncle Australia biotechnology company respectively with reference to documents such as McCusker,) antigen suspension 0.2ml, reinstated the 1%OVA ultrasonic atomizatio on the 28th day and suck, every day 20min, continuous 7 days.A group: use 0.9% normal saline as stated above, the C group: begin to irritate stomach wheat stilbene lung benefiting mixture 0.8ml before the sensitization, once-a-day, continuous 21 days.
1.4 Flow cytometry method: detect IL-4 and IFN-g in mice peripheral blood (extract eyeball and the get blood) cell with flow cytometer (BDFACSCalibur), use two-tube marker detection method, promptly adopt CD4, CD8 and IFN-gFITC tricolor marker one pipe, be used to detect the TH1 cell, CD4, CD8 and IL-4PE tricolor marker one pipe are used to detect the TH2 cell.
1.5 statistical analysis: use SPSS13.0 software, experimental data all (X ± s) expression, check with t with mean ± standard deviation by significance test.
2. result
2.1 mice toxicity trial: observing 7,14 days treatment groups and matched group does not all have death, and weight ratio sees Table 1, P〉0.05, zero difference.Loose stool occurred on the 1st day after only 1 mice is taken medicine, disappear after 2 days.
2.2 the mice sign changes: normal group: no change; Asthma group: mice shows as dysphoria after the sensitization, rapid breathing, and abdominal muscle is twitched, the back of a bow, hairs.
2.3 pathological observation: normal group mice trachea, alveolar and interval morphosis are normal, do not see hyperemia.Do not see hyperplasia; Little blood vessel of asthma group mice and bronchioles tube wall thicken, cellular infiltration, tissue edema; Little blood vessel of treatment group mice and bronchioles tube wall slightly thicken, and small amounts of cells is soaked into.
2.4 respectively organize IFN-g/ IL-4 changes of cytokine
: see Table 2
Table 1 test mice body weight record
Animal sex group number of animals is irritated stomach dosage body weight (g)
(only) (ml/20g) medication medication in 7 days 14 days before the medication
Male test group 10 0.8 23.43 ± 0.93 31.63 ± 1.01 36.14 ± 2.77
P 0.051 1.000
Matched group 10 0.8 23.14 ± 1.23 29.50 ± 1.56 31.89 ± 1.83
Female test group 10 0.8 23.26 ± 2.02 28.13 ± 1.16 30.19 ± 1.38
P 0.116 0.065
Table 2 is respectively organized IFN-g/ IL-4 changes of cytokine in the peripheral blood cells
Group number of mice (only) CD4 IL-4 CD4 γ-IFN
6 0.83 ± 0.41*, 6.36 ± 0.58 s are organized in treatment
Asthma group 6 7.72 ± 2.09** 1.23 ± 0.18 ss
Normal group 6 0.47 ± 0.09*** 1.22 ± 0.77sss
The treatment group is compared with asthma group, * P＜0.01, sP＜0.001; Compare * P＞0.05, sP＜0.01 with normal group
Asthma group is compared with normal group, * * P＜0.01, ssP＞0.05
3. conclusion: asthma is a kind of polygenic inheritance disease, has tangible family and assembles tendency, and be subjected to such environmental effects more obvious.Epidemiological study is found, brings out the asthma in acute attack most commonly encountered diseases because of being upper respiratory tract infection, accounts for 87.5%-94.62% according to Related domestic documents report upper respiratory tract infection rate.Studies show that asthma patient Th1/Th2 ratio is low than the normal person, and the expression advantage of Th2 type cytokines is the basic reason that causes chronic airway inflammation and airway hyper-reaction, therefore corrects the unbalance treatment of asthma that helps of Th1/Th2 ratio.Wheat stilbene lung benefiting mixture has remarkable statistical significance to mice TH1 cellular expression and asthma group and normal group, the treatment group is higher than asthma group and normal group (P＜0.001), the IL-4 measurement result shows that asthma group is higher than treatment group and normal group, show that its balance to the Th1/Th2 cell has positive regulating action, but IFN-g expresses in the pair cell facilitation is arranged, help the improvement and the long-term stability of symptoms of asthma.
Claims (6)
1. medicine for the treatment of children respiratory repeated infection is characterized in that this medicine made by the raw material of following weight portion: Radix Astragali 3-18 part, Radix Ophiopogonis 2-12 part, Rhizoma Atractylodis Macrocephalae 3-18 part, Poria 3-18 part, Fructus Schisandrae Chinensis 2-10 part, Fructus Mume 2-10 part, Pericarpium Citri Reticulatae 2-10 part, Radix Glycyrrhizae 2-8 part.
2. medicine according to claim 1 is characterized in that the preferred weight proportioning of above-mentioned raw materials is as follows: 6 parts of the Radixs Astragali, 4 parts of Radix Ophiopogonis, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts in Poria, 4 parts of Fructus Schisandrae Chinensis, 4 parts of Fructus Mumes, 4 parts of Pericarpium Citri Reticulataes, 3 parts in Radix Glycyrrhizae.
3. medicine according to claim 1 is characterized in that the preferred weight proportioning of above-mentioned raw materials is as follows: 9 parts of the Radixs Astragali, 6 parts of Radix Ophiopogonis, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts in Poria, 5 parts of Fructus Schisandrae Chinensis, 5 parts of Fructus Mumes, 5 parts of Pericarpium Citri Reticulataes, 4 parts in Radix Glycyrrhizae.
4. medicine according to claim 1 is characterized in that the preferred weight proportioning of above-mentioned raw materials is as follows: 18 parts of the Radixs Astragali, 9 parts of Radix Ophiopogonis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts in Poria, 8 parts of Fructus Schisandrae Chinensis, 8 parts of Fructus Mumes, 10 parts of Pericarpium Citri Reticulataes, 8 parts in Radix Glycyrrhizae.
5. according to the preparation method of claim 1,2,3,4 described medicines, may further comprise the steps: add multi-function extractor after getting eight flavor Chinese medicine weighings of weight proportion in the prescription, after water fully soaks, add water and cross powder 2-3 centimetre and decoct twice, 1.5 hours for the first time, 1 hour for the second time, decocting liquid filtered, and merged, soak to put and get supernatant concentration more than 12 hours to about 950ml, add sucrose 100g while hot, sodium benzoate 2 g stir evenly.
6. as the quality determining method of medicine as described in the claim 1,2,3,4, it is characterized in that this method comprises following discriminating:
A: the thing 20ml that gets it filled, extract 2 times with water saturated n-butyl alcohol jolting, each 20ml merge extractive liquid,, with ammonia solution washing 2 times, each 30 ml, the saturated water washing of reuse n-butyl alcohol 2 times, each 30 ml, n-butyl alcohol evaporate to dryness; Residue adds methanol test solution 1 ml makes dissolving, as need testing solution; Other gets the astragaloside reference substance, adds methanol and makes the solution that per 1 ml contains 0.5mg, product solution in contrast; Draw above-mentioned test sample 5ul, reference substance solution 2ul, put respectively on same silica gel g thin-layer plate, placing stratified lower floor solution below 10 ℃ with chloroform-methanol-water (13:7:2) is developing solvent, launch, take out, airing, spray are with 10% sulphuric acid ethanol (V/V) solution, and it is clear to be heated to the speckle color at 105 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of identical color;
B: thing 20 ml that get it filled, extract 2 times with the ethyl acetate jolting, each 20 ml merge ethyl acetate liquid, and evaporate to dryness, residue add methanol 1 ml makes dissolving, as need testing solution; Other gets the Hesperidin reference substance, adds methanol and makes saturated solution, in contrast product solution; Drawing above-mentioned two kinds of each 1ul of test liquid, put respectively on same polyamide film, is developing solvent with chloroform-acetone-methanol (5:1:1), launch, take out, dry, spray is placed more than 30 minutes with 2% aluminum chloride alcoholic solution, puts under the uviol lamp (365nm) and inspects; In the test sample chromatograph, be on the corresponding position of reference substance chromatograph, show the fluorescence speckle of same color;
C: the thing 10ml that gets it filled, slowly Dropwise 5 0% sulfuric acid solution 1 ml leaves standstill and makes precipitation, centrifugal, abandoning supernatant, precipitation washes with water 2 times, and each 10 ml get precipitation and add ethanol 5 ml and make dissolving, and are centrifugal, get supernatant as need testing solution; Extracting liquorice acid ammonium reference substance adds ethanol and makes the solution that per 1 ml contains 0.5mg, product solution in contrast in addition; Drawing above-mentioned need testing solution 15ul, reference substance solution 2ul, put respectively on same silica GF254 lamellae, is developing solvent with ethyl acetate-formic acid-glacial acetic acid-water (15:1:1:2), launches, and takes out, and dries, and puts under the uviol lamp (254nm) and inspects; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100041173A CN102078508B (en) | 2011-01-11 | 2011-01-11 | Medicine for treating infantile respiratory tract recurrent infection, preparation method thereof and quality control method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100041173A CN102078508B (en) | 2011-01-11 | 2011-01-11 | Medicine for treating infantile respiratory tract recurrent infection, preparation method thereof and quality control method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102078508A true CN102078508A (en) | 2011-06-01 |
| CN102078508B CN102078508B (en) | 2013-04-24 |
Family
ID=44084832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100041173A Active CN102078508B (en) | 2011-01-11 | 2011-01-11 | Medicine for treating infantile respiratory tract recurrent infection, preparation method thereof and quality control method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102078508B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102225193A (en) * | 2011-06-23 | 2011-10-26 | 李梅 | Traditional Chinese medicine composition for controlling recurrent respiratory tract infection in children |
| CN102488766A (en) * | 2011-12-21 | 2012-06-13 | 张群 | Chinese medicinal effective fraction composition for treating cough and preparation method thereof |
| CN104825781A (en) * | 2015-05-11 | 2015-08-12 | 宋宜德 | Traditional Chinese medicine for treating chronic rhinitis and bronchitis |
| CN105327116A (en) * | 2015-11-06 | 2016-02-17 | 李艺腾 | Traditional Chinese medicine composition for treating children with reccurent respiratory tract infections |
| CN107884489A (en) * | 2017-11-07 | 2018-04-06 | 贵阳德昌祥药业有限公司 | A kind of detection method of Zaizao Pill |
| CN108567896A (en) * | 2018-06-05 | 2018-09-25 | 高密市人民医院 | A kind of decoction of medicinal ingredients acting on the patients such as respiratory failure |
| CN112946129A (en) * | 2021-02-03 | 2021-06-11 | 桂林三金药业股份有限公司 | Quality detection method of antidiarrheal syrup |
-
2011
- 2011-01-11 CN CN2011100041173A patent/CN102078508B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 王丽英: "脾氨肽对反复呼吸道感染患儿Th1_Th2细胞因子的影响", 《中国全科医学》 * |
| 陈培丽等: "麦芪益肺合剂对哮喘小鼠Th1/Th2平衡的影响及安全性研究", 《中国药房》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102225193A (en) * | 2011-06-23 | 2011-10-26 | 李梅 | Traditional Chinese medicine composition for controlling recurrent respiratory tract infection in children |
| CN102225193B (en) * | 2011-06-23 | 2012-09-12 | 李梅 | Traditional Chinese medicine composition for controlling recurrent respiratory tract infection of children |
| CN102488766A (en) * | 2011-12-21 | 2012-06-13 | 张群 | Chinese medicinal effective fraction composition for treating cough and preparation method thereof |
| CN104825781A (en) * | 2015-05-11 | 2015-08-12 | 宋宜德 | Traditional Chinese medicine for treating chronic rhinitis and bronchitis |
| CN105327116A (en) * | 2015-11-06 | 2016-02-17 | 李艺腾 | Traditional Chinese medicine composition for treating children with reccurent respiratory tract infections |
| CN105327116B (en) * | 2015-11-06 | 2019-06-18 | 李艺腾 | A kind of Chinese medicine composition for treating Chinese medicinel |
| CN107884489A (en) * | 2017-11-07 | 2018-04-06 | 贵阳德昌祥药业有限公司 | A kind of detection method of Zaizao Pill |
| CN108567896A (en) * | 2018-06-05 | 2018-09-25 | 高密市人民医院 | A kind of decoction of medicinal ingredients acting on the patients such as respiratory failure |
| CN112946129A (en) * | 2021-02-03 | 2021-06-11 | 桂林三金药业股份有限公司 | Quality detection method of antidiarrheal syrup |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102078508B (en) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078508B (en) | Medicine for treating infantile respiratory tract recurrent infection, preparation method thereof and quality control method thereof | |
| CN100425277C (en) | Composition with function of relieving cough and calming asthma and preparing method | |
| CN101347612B (en) | Compound medicament for treating common cold cough and acute/chronic bronchitis, and preparation method thereof | |
| CN101310751A (en) | Traditional Chinese medicine composition for replenishing qi and blood, preparation method and quality control method thereof | |
| CN100400075C (en) | Qi-invigorating, blood-nourishing medicinal composition and its preparing method | |
| CN102380061A (en) | Chinese medicinal composition for eliminating and dissolving phlegm and relieving cough, as well as preparation method and application thereof | |
| CN101396486B (en) | Traditional Chinese medicine composition for treating cough and asthma and preparation and quality control method thereof | |
| CN1957999B (en) | Composition of Chinese traditional medicine, preparation method, and checking method | |
| CN100574768C (en) | A kind of anticancer pharmaceutical composition and its production and use | |
| CN100418561C (en) | Chinese medicine composition and its prepn process and quality control method | |
| ES2703173T3 (en) | Composition of use in the prevention and treatment of allergic diseases | |
| CN103120790B (en) | Traditional Chinese medicine granules for treating chronic hepatitis and forepart hepetocirrhosis and preparation method thereof | |
| CN102652774B (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN108743893A (en) | The preparation method and applications of clearing lung-heat soup side's Chinese medical extract | |
| CN101670088B (en) | Traditional Chinese medicine composite for treating acute/chronic bronchitis | |
| CN100493522C (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN102225144B (en) | Traditional Chinese medicine compound for treating cough and asthma and preparation method thereof | |
| CN101396441B (en) | Traditional Chinese medicine composition for treating blood stasis syndrome of multi viscera organs incompetence syndrome | |
| CN103919845B (en) | A kind of pharmaceutical composition for improving anoxia endurance and its preparation method and application | |
| CN105998244B (en) | A kind of Chinese medicine preparation for chronic heart failure | |
| CN103768305A (en) | Medicine for treating spleen-deficiency diarrhea type IBS (Irritable Bowel Syndrome) and manufacturing method thereof | |
| CN104547546B (en) | A kind of Chinese medicine composition of kidney tonifying moistening lung and its preparation method of different dosage forms | |
| CN102988864B (en) | Shenling Baizhu preparation and novel use thereof | |
| CN102068669B (en) | Medicament for treating infant hepatitis syndrome, and preparation method and quality control method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |